Your Molecule matters

A continuum of small to large scale Custom API capabilities

As a Global CDMO we support at every stage of the product lifecycle.

With 25 years of experience in process development, scale-up and ongoing cGMP manufacturing of small molecule APIs, we support emerging, specialty and large pharmaceutical customers for their drug substance or drug delivery needs.

Discover

Highly efficient cGMP manufacturing capabilities

As a fully integrated CDMO, Seqens is uniquely positioned to address the continuum of the API value chain : API, HPAPI, cGMP & non-GMP intermediates, RSM, controlled substances, excipient for drug delivery

Discover

A trusted supplier
of proprietary APIs

More than 50 APIs have been successfully launched in the United States, Europe and Japan with consistently superior quality, reliability and customer service, supported by regulatory documentation to meet the most stringent standards from local agencies

Discover
Learn more about seqens group

A continuum of custom synthesis technologies

8 industrial plants and 3 R&D centers in Europe, North America and Asia.

More than 300 scientists, engineers and experts develop tailor-made solutions for its customers and ensure that products are successfully transferred into production.

Discover our R&D services

Newsroom

#Live

General / Research and Development

Flow chemistry for efficient and safe synthesis of APIs and intermediates

DOWNLOAD THE PRESS RELEASE Approximately 2,800 active pharmaceutical ingredients (APIs) are currently marketed, 70% of which being synthetic chemical molecules.Their…
Read more See all news
API Manufacturing / General

API lifecycle management: A CDMO perspective

Didier Combis of Seqens CDMO explains why pharmaceutical companies should consider the specifics of the API when dealing with drug lifecycle management…
Read more See all news
API Manufacturing / General

Developing Controlled Substances Requires a Whole New Level of Global Diligence

4 Best Practices For Taking the Right Precautions to Develop Safe and Effective controlled Substances By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO…
Read more See all news
API Manufacturing / Articles / General

The Growth of the Generic Drug Marketplace

The Growth of the Generic Drug Marketplace: A Win-Win for Industry and Patients By Laurent Alexandre, Director, Proprietary APIs, Seqens CDMO Some…
Read more See all news
API Manufacturing / Articles / General / Research and Development

Faster, Less Costly Cinacalcet Production is Among CDMO Responses to Alleviate Rising Cost of Drugs, Impact of Tariffs

Proprietary intermediates produced in Europe, U.S. rather than imported Across the world, the pressure to cut drug price costs has never been greater.
Read more See all news
API Manufacturing

Deriving Value from Integrated cGMP and Pre-GMP Manufacturing Operations

Working with Contract Development & Manufacturing Organizations (CDMOs) in Asia has become a popular strategy for European and U.S.-based sponsors because of the associated lower costs to manufacture complex Active Pharmaceutical Ingredients (APIs).
Read more See all news
General

SEQENS is committed to the development and production of critical molecules in France

SEQENS has decided to invest €65M to increase its development and production capacities for active ingredients and pharmaceutical intermediates and to accelerate…
Read more See all news
API Manufacturing / General

A new large scale potent API manufacturing unit at SEQENS Villeneuve-La-Garenne

Shifting needs in the pharmaceutical market are driving a stronger demand for specialized production units to manufacture highly potent active…
Read more See all news
General

Lahr's Site: a Seqens CDMO plant.

Founded in 1991, The site of Lahr is part of SEQENS CDMO since mid-2015. The site is specialized in the development and manufacturing…
Read more See all news

#Jobs

See all our offers

Seqens CDMO global presence

Use interactive map
0

6 cGMP/FDA inspected sites in EU & US

0

Pre-GMP sites for RSMs & Intermediates

0

M3 capacity

0

DMFs for commercial APIs

0

Scientists, experts and engineers

0

R&D centers in UE and US